Clinical trial
Lamivudine and Adefovir to Treat Chronic Hepatitis B
NCT00023309 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH · Completed
Key facts
| NCT number | NCT00023309 |
|---|---|
| Title | Lamivudine and Adefovir to Treat Chronic Hepatitis B |
| Official title | Combination of Lamivudine and Adefovir Dipivoxil for Treatment of Chronic Hepatitis B |
| Lead sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HBV (Hepatitis B Virus), Hepatitis B, Hepatitis |
| Intervention type | Drug |
| Interventions | Lamivudine and adefovir, Adefovir alone |
| Enrollment | 41 |
| Start date | Aug 1, 2001 |
| Primary completion | Apr 1, 2010 |
| Completion | Aug 1, 2013 |
| First posted | Sep 3, 2001 |
| Last update posted | Sep 23, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: